Item 7.01 Regulation FD Disclosure. On August 18, 2026, Anthropic, PBC (“Anthropic”) published a blog post announcing that it had received data back for a multi-arm protein design campaign against 15 targets using Claude Opus 4.8 and Mythos Preview, and that it had chosen Twist Bioscience Corporation (the “Company”) as one of its independent evaluators to rapidly produce at scale these AI-designed…
Filed Aug 19, 2026Accepted Aug 18, 2026, 6:15 PM EDTCIK 1581280Accession 0001581280-26-000050
At Twist Bioscience, our customizable solutions across the biological continuum raise the bar in diagnostics, therapeutics, industrial, agriculture and research markets. We drive innovation with confidence, without compromise. Whether delivering oligos, genes, proteins, libraries, characterization data, antibody discovery solutions, or NGS workflow tools, our scientific expertise and exceptional customer experience help navigate complex challenges, all with precision and at the scale and speed customers require. By enhancing R&D efficiency at every turn, we give scientists more shots on goal - more experiments, more iterations, more chances for remarkable discoveries.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On August 18, 2026, Anthropic, PBC (“Anthropic”) published a blog post announcing that it had received data back for a multi-arm protein design campaign against 15 targets using Claude Opus 4.8 and Mythos Preview, and that it had chosen Twist Bioscience Corporation (the “Company”) as one of its independent evaluators to rapidly produce at scale these AI-designed proteins and test these designs for binding. The blog post is available at www.anthropic.com/research/Claude-accelerates-protein-design. Information on or accessible through Anthropic’s website is not incorporated by reference in this Current Report on Form 8-K.
The information furnished in this Item 7.01 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.